FY2028 EPS Forecast for Delcath Systems Lowered by Analyst

Delcath Systems, Inc. (NASDAQ:DCTH) – Stock analysts at HC Wainwright cut their FY2028 earnings per share (EPS) estimates for Delcath Systems in a report released on Monday, November 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $1.46 per share for the year, down from their prior forecast of $1.69. HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($1.64) per share.

Other analysts have also recently issued reports about the company. Canaccord Genuity Group reiterated a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a research report on Friday, October 18th. StockNews.com upgraded Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. Finally, Stephens restated a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $21.50.

Delcath Systems Trading Down 3.0 %

Delcath Systems stock opened at $9.41 on Wednesday. Delcath Systems has a 52 week low of $2.25 and a 52 week high of $12.88. The stock has a fifty day moving average price of $9.74 and a 200 day moving average price of $8.43.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Riverwater Partners LLC bought a new stake in shares of Delcath Systems during the third quarter worth about $161,000. Levin Capital Strategies L.P. boosted its position in Delcath Systems by 12.2% during the 1st quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock valued at $262,000 after buying an additional 5,969 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Delcath Systems in the 2nd quarter worth about $370,000. Renaissance Technologies LLC purchased a new position in Delcath Systems during the 2nd quarter valued at about $694,000. Finally, Marshall Wace LLP lifted its position in Delcath Systems by 7.0% during the 2nd quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock valued at $776,000 after acquiring an additional 6,066 shares during the period. 61.12% of the stock is owned by institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.